Compare Abeona Therapeutics Inc (ABEO) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Levi Strauss & Co. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Levi Strauss & Co. trades at $24.48 (market cap $9.48B). The key difference: Levi Strauss & Co. is far larger — about 25.4× Abeona Therapeutics Inc's market cap, and Levi Strauss & Co. pays a 2.27% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LEVI | |
|---|---|---|
Market Cap | $373.32M | $9.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $24.83 |
52-Week Low | $4.17 | $17.92 |
Enterprise Value | $228.22M | $10.99B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Levi Strauss (LEVI) trades at $24.66, up 1.02% with bullish technical indicators and strong earnings momentum after three consecutive quarterly beats. The company demonstrates robust profitability with a 61.69% gross margin and 9.52% net margin, supported by a $29.00 analyst consensus price target representing 17.6% upside. Recent news highlights Q2 2026 earnings anticipation and strategic focus on women's apparel expansion.
Outlook remains positive with earnings growth and dividend stability, though risks include inflationary pressures and competitive retail dynamics. The stock's current valuation at 18.15x P/E appears reasonable given 29.19% ROE, but investors should monitor Q2 results on July 8 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
